Drugs / Convalescent Serum
last change Sep 2020 re-read 2 minutes ago

Convalescent Serum

Developed for
COVID-19
Investigated by
The Camelot Foundation

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT04349410 Apr → Sep 2020 COVID-19 The Camelot Foundation Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Convalescent Serum ClinicalTrials.gov intervention name — accepted as the source's own label NCT04349410
Route Intravenous “Each unit intravenously infused over 4-hours.” NCT04349410